AstraZeneca has been exploring a potential merger with U.S. pharmaceutical rival Bristol Myers Squibb that could create one of the world's largest drugmakers valued at nearly US$400 billion (S$512 billion) [1, 2, 3, 4].
The two companies have conducted discussions in recent months, with the deal expected to materialize soon, though it could also be delayed or fall apart, according to sources [1, 2, 4]. AstraZeneca declined to comment on the talks, and Bristol Myers Squibb did not respond to requests for comment [1, 2, 3, 4].
This potential merger comes roughly a dozen years after AstraZeneca resisted a takeover bid from Pfizer, marking another step in the company’s growth strategy [1, 2, 4]. Under CEO Pascal Soriot’s 14-year leadership, AstraZeneca’s share price has more than quadrupled, reflecting strong operational performance [2, 4].
AstraZeneca reported strong sales growth in the second quarter of 2026, driven by demand for cancer and rare disease drugs. Its cancer treatments generated nearly US$25 billion in sales in 2025, accounting for about half its total revenue. Cardiovascular, renal, and metabolism therapies followed with approximately US$12 billion in 2025 sales [2, 4].
In 2025, AstraZeneca announced plans for a direct listing on the U.S. stock market while maintaining its London listing, signaling its intent to strengthen its presence in the U.S. where Bristol Myers Squibb is based [2, 4].
The Financial Times first reported the merger talks on August 2, 2026, bringing widespread attention to the potential megadeal [1, 2, 3, 4].
With talks ongoing, the companies have not provided a timeline for a deal announcement or completion, leaving the final outcome uncertain [1, 2, 4].
